Physicians
I-SPY 2 is a collaborative research effort that uses genetic and biological markers from individual patients’ tumors to screen several promising new treatments simultaneously and allows doctors to quickly measure the effectiveness of the treatment prior to removing the tumor.
Patients
I-SPY 2 aims to lower the development costs of new cancer treatments and significantly reduce the time for new treatments to reach patients in need. Additionally, it will enable more drugs, with smaller patient populations, to reach the market.
Investigators
I-SPY 2 is a groundbreaking clinical trial that uses a novel process for rapid, focused clinical development of paired oncologic therapies and biomarkers.
I-SPY 2 is an Innovative public-private collaboration that combines Personalized Medicine & Novel Trial Design to develop new cancer treatments much faster and for much less cost
What Is I-SPY 2?
I-SPY 2 TRIAL is a neoadjuvant clinical trial designed to test Phase II investigational agents in combination with standard chemotherapy in a curable patient population. By employing an innovative ‘adaptive trial design’–which uses patient outcomes to immediately inform treatment assignments for subsequent trial participants—I-SPY 2 can test new treatments in half the time, at a fraction of the cost and with significantly fewer participants.
Who Should Participate?
Today most women with breast cancer receive standard chemotherapy. We know that some breast cancers respond well to this treatment but some do not. The I-SPY 2 TRIAL is a clinical trial for women with newly diagnosed, locally advanced breast cancer to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone prior to having surgery. The I-SPY 2 TRIAL will use genetic or biological markers (“biomarkers”) from individual patients’ tumors to screen promising new treatments, identifying which treatments are most effective in specific types of patients.
